
7.	INCOME TAX

At June 30, 2015, net operating loss carry forwards of our foreign and domestic subsidiaries totaled $27.2 million, some of which begin to expire in 2020. For accounting purposes, the estimated tax effect of this net operating loss carry forward results in a deferred tax asset. The deferred tax asset associated with these losses was $8.7 million with a valuation allowance of $4.6 million charged against this deferred tax asset assuming these losses will not be fully realized. At December 31, 2014, these net operating loss carry forwards totaled $26.7 million, and the deferred tax asset was $8.5 million with a valuation allowance of $5.1 million charged against this deferred tax asset assuming these losses will not be fully realized.

Our income tax returns are subject to examination in numerous state, federal and foreign jurisdictions due to the multiple income tax jurisdictions in which we operate. We are currently not aware of any open examinations by the various government jurisdictions. As of June 30, 2015, we have no liability recorded as an uncertain tax benefit. The Credit for Increasing Research Activities expired for the year ending December 31, 2014, and for the six months ended June 30, 2015, we have not recorded a research credit benefit.